Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

NCT02404051 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

745

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Breast Cancer
Hormone Receptor Positive Tumor
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Locally Advanced Malignant Neoplasm

Interventions

DRUG: Everolimus
DRUG: Exemestane
DRUG: Fulvestrant

Sponsor

Consorzio Oncotech

Collaborators

[object Object]